Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Whitehawk Therapeutics, Inc. Director's Dealing 2021

Jul 2, 2021

34276_dirs_2021-07-02_3307965f-7bdd-4096-a1c3-cce148a6950a.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Aerpio Pharmaceuticals, Inc. (ARPO)
CIK: 0001422142
Period of Report: 2021-06-30

Reporting Person: Dalal Anupam (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-06-30 Common Stock A 7400 $1.52 Acquired 16959 Direct

Footnotes

F1: Represents common stock equity awards issued under the Issuer's 2017 Stock Option and Incentive Plan to the non-employee directors of the Issuer in lieu of cash retainer fees pursuant to its non-employee director compensation policy. The price per share was based on the average closing price of the Company's common stock over the quarter ended June 30, 2021.